A. Forner, M. Reig, J. Bruix, and . Hepatocellular, Lancet, vol.391, pp.1301-1315, 2018.

A. Kreso and J. E. Dick, Evolution of the cancer stem cell model, Cell Stem Cell, vol.14, pp.275-91, 2014.

L. Ahrlund-richter and M. J. Hendrix, Oncofetal signaling as a target for cancer therapy, Semin Cancer Biol, vol.29, pp.1-2, 2014.

D. M. Xiang, W. Sun, and T. Zhou, Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance, Gut, vol.68, pp.1858-71, 2019.

K. Komorowska, A. Doyle, and M. Wahlestedt, Hepatic leukemia factor maintains quiescence of hematopoietic stem cells and protects the stem cell pool during regeneration, Cell Rep, vol.21, pp.3514-3537, 2017.

U. Fischer, M. Forster, and A. Rinaldi, Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options, Nat Genet, vol.47, pp.1020-1029, 2015.

D. M. Xiang, W. Sun, and B. F. Ning, The HLF/IL-6/ STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis, Gut, vol.67, pp.1704-1719, 2018.

K. Fekir, H. Dubois-pot-schneider, and R. Désert, Retrodifferentiation of human tumor hepatocytes to stem cells leads to metabolic reprogramming and chemoresistance, Cancer Res, vol.79, pp.1869-83, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02087900

S. Maeda and M. Karin, Oncogene at last--c-Jun promotes liver cancer in mice, Cancer Cell, vol.3, pp.102-106, 2003.

W. Chen, W. Xiao, and K. Zhang, Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma, Preliminary Clinical Evidence. Sci Rep, vol.6, p.22976, 2016.

F. Thomas, E. Donnadieu, and G. M. Charriere, Is adaptive therapy natural?, PLoS Biol, vol.16, p.2007066, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01887358